ReviewCurrent hypertension reports2022
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Review in Current hypertension reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 28 citations in OpenAlex.
- Anaemia predicts iron homoeostasis dysregulation and modulates the response to empagliflozin in heart failure with reduced ejection fraction: the EMPATROPISM-FE trial.European heart journal · 2025Trial
- Combined Aldosterone Synthase and SGLT2 Inhibition: A Recipe for Success in CKD with Uncontrolled Blood Pressure?Current hypertension reports · 2026Review
- Associations Between Metabolic Score for Visceral Fat and Venous Thromboembolism Among 118 619 Participants With Metabolic Syndrome: Insights From Epidemiology to Genetic Susceptibility.Journal of the American Heart Association · 2026Article
- Urine and plasma metanephrine concentrations in cats with chronic kidney disease: characterization and correlation with biomarkers of renal function.Journal of veterinary internal medicine · 2026Article
- Dapagliflozin lowers blood pressure via regulating the sympathetic neural activity in the paraventricular nucleus of hypothalamus in normal mice.Frontiers in endocrinology · 2026Article
- Complementary Yet Distinct Roles of GLP-1 Receptor Agonists and SGLT2 Inhibitors in Cardiovascular Risk Reduction.Biomedicines · 2025Review
- Phenotypic patterns of metabolic dysfunction-associated steatotic liver disease in type 2 diabetes: The impact of insulin.European journal of clinical investigation · 2025Observational
- Emerging Perspectives on the Impact of Diabetes Mellitus and Anti-Diabetic Drugs on Premenstrual Syndrome. A Narrative Review.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2024Review
- Sodium glucose cotransporter-2 inhibitors and heart disease: Current perspectives.World journal of cardiology · 2024Review
- SGLT2 and SGLT1 inhibitors suppress the activities of the RVLM neurons in newborn Wistar rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status.International journal of molecular sciences · 2023Review
- Management of Type 2 Diabetes in Frail Older Adults.Drugs & aging · 2023Article
- The Neuronal and Non-Neuronal Pathways of Sodium-Glucose Cotransporter-2 Inhibitor on Body Weight-Loss and Insulin Resistance.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis.Frontiers in cardiovascular medicine · 2023Review
- The Mechanism of Sodium-Glucose Cotransporter-2 Inhibitors in Reducing Uric Acid in Type 2 Diabetes Mellitus.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Article
- Metabolic Syndrome-Related Kidney Injury: A Review and Update.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of reviewThe moderate glucose-lowering effect of sodium glucose co-transporter 2 (SGLT2) inhibitors is unlikely to explain SGLT2 inhibitor-mediated beneficial outcomes, and unravelling the underlying mechanisms is a high priority in the research community. Given the dominant pathophysiologic role of the sympathetic nervous system activation in conditions such as hypertension and perturbed glucose homeostasis, it is pertinent to postulate that SGLT2 inhibitors may exert their beneficial effects at least in part via sympathetic inhibition. RECENT
findingsSGLT2 inhibitors have shown enormous potential to improve cardiovascular outcomes in patients with type 2 diabetes, and their therapeutic potential is currently being investigated in a range of associated comorbidities such as heart failure and chronic kidney disease. Indeed, recent experimental data in relevant animal models highlight a bidirectional interaction between sympathetic nervous system activation and SGLT2 expression, and this facilitates several of the features associated with SGLT2 inhibition observed in clinical trials including improved glucose metabolism, weight loss, increased diuresis, and lowering of blood pressure. Currently available data highlight the various levels of interaction between the sympathetic nervous system and SGLT2 expression and explores the potential for SGLT2 inhibition as a therapeutic strategy in conditions commonly characterised by sympathetic activation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.